NASDAQ:ALPN Alpine Immune Sciences Q1 2024 Earnings Report Profile Alpine Immune Sciences EPS ResultsActual EPS-$0.28Consensus EPS -$0.43Beat/MissBeat by +$0.15One Year Ago EPSN/AAlpine Immune Sciences Revenue ResultsActual Revenue$7.03 millionExpected Revenue$5.50 millionBeat/MissBeat by +$1.53 millionYoY Revenue GrowthN/AAlpine Immune Sciences Announcement DetailsQuarterQ1 2024Date5/9/2024TimeN/AConference Call DateThursday, May 9, 2024Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Company ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alpine Immune Sciences Earnings HeadlinesAlpine Immune Sciences Inc.January 10, 2025 | thestreet.comFrazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture PartnersJanuary 9, 2025 | finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 15 at 2:00 AM | Brownstone Research (Ad)What 11 Analyst Ratings Have To Say About Alpine Immune SciencesMay 16, 2024 | markets.businessinsider.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | businesswire.comSee More Alpine Immune Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpine Immune Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpine Immune Sciences and other key companies, straight to your email. Email Address About Alpine Immune SciencesAlpine Immune Sciences (NASDAQ:ALPN) operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.View Alpine Immune Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings ASML (7/16/2025)Kinder Morgan (7/16/2025)U.S. Bancorp (7/16/2025)Bank of America (7/16/2025)Prologis (7/16/2025)Morgan Stanley (7/16/2025)Johnson & Johnson (7/16/2025)The PNC Financial Services Group (7/16/2025)Progressive (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
